IA2030 Scorecard
—Global
- 1.2 Health workforce1.6 Vaccine safety2.1 Political and financial commitment2.2 Demand for immunization3.2 High & equitable coverage4.1 Life-course vaccination5.1 Outbreak detection and response6.1 Healthy global markets for vaccines6.2 Financial resources for imm. programmes6.3 Imm. expenditure from domestic resources7.1 Capacity for innovation
Type to select a Country
SP 4: Life Course & Integration
4.1
Life-course vaccination
Breadth of protection (Mean Coverage across 12 antigens, %)—Global
Average (Mean) Coverage
71%
Baseline
68%
2021
72%
2022
3rd dose of diphtheria-tetanus-pertussis-containing vaccine (DTPcv3)
86%
Baseline
81%
2021
84%
2022
3rd dose of hepatitis B vaccine (HepB3)
86%
Baseline
81%
2021
84%
2022
3rd dose of Haemophilus influenzae type b vaccine (Hib3)
74%
Baseline
72%
2021
76%
2022
Final dose of human papillomavirus vaccine (HPV)
14%
Baseline
13%
2021
15%
2022
1st dose of inactivated poliovirus vaccine (IPV1)
85%
Baseline
81%
2021
85%
2022
1st dose of measles-containing vaccine (MCV1)
86%
Baseline
81%
2021
83%
2022
2nd dose of measles-containing vaccine (MCV2)
71%
Baseline
71%
2021
74%
2022
3rd dose of pneumococcal conjugate vaccine (PCV3)
51%
Baseline
51%
2021
60%
2022
3rd dose of polio vaccine (POL3)
87%
Baseline
81%
2021
84%
2022
1st dose of rubella-containing vaccine (RCV1)
69%
Baseline
66%
2021
68%
2022
Final dose of rotavirus vaccine series (ROTAC)
40%
Baseline
48%
2021
51%
2022
Summary Table
| Antigen | Baseline (2019) | 2021 | 2022 |
|---|---|---|---|
| Average (Mean) Coverage | 71% | 68% | 72% |
| 3rd dose of diphtheria-tetanus-pertussis-containing vaccine (DTPcv3) | 86% | 81% | 84% |
| 3rd dose of hepatitis B vaccine (HepB3) | 86% | 81% | 84% |
| 3rd dose of Haemophilus influenzae type b vaccine (Hib3) | 74% | 72% | 76% |
| Final dose of human papillomavirus vaccine (HPV) | 14% | 13% | 15% |
| 1st dose of inactivated poliovirus vaccine (IPV1) | 85% | 81% | 85% |
| 1st dose of measles-containing vaccine (MCV1) | 86% | 81% | 83% |
| 2nd dose of measles-containing vaccine (MCV2) | 71% | 71% | 74% |
| 3rd dose of pneumococcal conjugate vaccine (PCV3) | 51% | 51% | 60% |
| 3rd dose of polio vaccine (POL3) | 87% | 81% | 84% |
| 1st dose of rubella-containing vaccine (RCV1) | 69% | 66% | 68% |
| Final dose of rotavirus vaccine series (ROTAC) | 40% | 48% | 51% |
Definition: Mean coverage for all WHO-recommended vaccine antigens
- Numerator: Sum of the coverage for the following antigens at the level of interest – Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type B (Hib), Measles 1st dose (MCV), Measles 2nd dose (MCV2), pneumococcus, Polio (POL3), Inactivated Poliovirus Vaccine (IPV), Rubella, Rotavirus, and Human Papillomavirus (HPV).
- Denominator: Number of all antigens included for the indicator calculation, regardless of whether antigen has been introduced at the level of interest (denominator equals 13).
Method of estimation:
Step 1) Calculate the average of the coverage achieved at the level of interest (e.g., country level, global, WHO regional, etc.)
- Following antigens are included, regardless of whether the antigen has been introduced – Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib, Measles, Measles 2nd dose, Pneumo, Polio, IPV, Rubella, Rota, and HPV.
- If coverage is not available at the level of interest, calculate coverage accordingly (weighted by population) before calculating the indicator value.
Data source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), WHO/UNICEF HPV Estimates
Accessed: undefined
